Artykuły w czasopismach na temat „Marine sarcoma”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Marine sarcoma”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Su, Bor-Chyuan, Giun-Yi Hung, Yun-Chieh Tu, Wei-Chen Yeh, Meng-Chieh Lin i Jyh-Yih Chen. "Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization". Marine Drugs 19, nr 2 (5.02.2021): 93. http://dx.doi.org/10.3390/md19020093.
Pełny tekst źródłaSu, Bor-Chyuan, Chao-Chin Li, Jiun-Lin Horng i Jyh-Yih Chen. "Calcium-Dependent Calpain Activation-Mediated Mitochondrial Dysfunction and Oxidative Stress Are Required for Cytotoxicity of Epinecidin-1 in Human Synovial Sarcoma SW982 Cells". International Journal of Molecular Sciences 21, nr 6 (19.03.2020): 2109. http://dx.doi.org/10.3390/ijms21062109.
Pełny tekst źródłaDelaloge, S., A. Yovine, A. Taamma, M. Riofrio, E. Brain, E. Raymond, P. Cottu i in. "Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity". Journal of Clinical Oncology 19, nr 5 (1.03.2001): 1248–55. http://dx.doi.org/10.1200/jco.2001.19.5.1248.
Pełny tekst źródłaGarcia-Carbonero, R., J. G. Supko, J. Manola, M. V. Seiden, D. Harmon, D. P. Ryan, M. T. Quigley i in. "Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy". Journal of Clinical Oncology 22, nr 8 (15.04.2004): 1480–90. http://dx.doi.org/10.1200/jco.2004.02.098.
Pełny tekst źródłaAlthagbi, Hanan I., Walied M. Alarif, Khalid O. Al-Footy i Ahmed Abdel-Lateff. "Marine-Derived Macrocyclic Alkaloids (MDMAs): Chemical and Biological Diversity". Marine Drugs 18, nr 7 (17.07.2020): 368. http://dx.doi.org/10.3390/md18070368.
Pełny tekst źródłaMorgan, J. A., A. Le Cesne, S. Chawla, M. von Mehren, S. Schuetze, P. G. Casali, A. Nieto, Y. Elsayed, M. A. Izquierdo i G. D. Demetri. "Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 10060. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10060.
Pełny tekst źródłaJimeno, Jose, Robert G. Maki, Paolo Casali, Glynn Faircloth, Nerea Martinez, Antonio Nieto, Salvador Cañigueral i Kenneth Rinehart. "Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma". Current Opinion in Orthopaedics 14, nr 6 (grudzień 2003): 419–28. http://dx.doi.org/10.1097/00001433-200312000-00011.
Pełny tekst źródłaPierce, J. H., i S. A. Aaronson. "Myeloid cell transformation by ras-containing murine sarcoma viruses". Molecular and Cellular Biology 5, nr 4 (kwiecień 1985): 667–74. http://dx.doi.org/10.1128/mcb.5.4.667-674.1985.
Pełny tekst źródłaPierce, J. H., i S. A. Aaronson. "Myeloid cell transformation by ras-containing murine sarcoma viruses." Molecular and Cellular Biology 5, nr 4 (kwiecień 1985): 667–74. http://dx.doi.org/10.1128/mcb.5.4.667.
Pełny tekst źródłaPecoraro, Camilla, Francesca Terrana, Giovanna Panzeca, Barbara Parrino, Stella Cascioferro, Patrizia Diana, Elisa Giovannetti i Daniela Carbone. "Nortopsentins as Leads from Marine Organisms for Anticancer and Anti-Inflammatory Agent Development". Molecules 28, nr 18 (5.09.2023): 6450. http://dx.doi.org/10.3390/molecules28186450.
Pełny tekst źródłaShamai, Sivan, i Ofer Merimsky. "Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): 11060. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.11060.
Pełny tekst źródłaHayashi, Keita, Peter Walde, Tatsuhiko Miyazaki, Kenshi Sakayama, Atsushi Nakamura, Kenji Kameda, Seizo Masuda, Hiroshi Umakoshi i Keiichi Kato. "Active Targeting to Osteosarcoma Cells and Apoptotic Cell Death Induction by the Novel Lectin Eucheuma serra Agglutinin Isolated from a Marine Red Alga". Journal of Drug Delivery 2012 (27.12.2012): 1–11. http://dx.doi.org/10.1155/2012/842785.
Pełny tekst źródłaPonnusamy, Nirmaladevi, Rajasree Odumpatta, Pavithra Damodharan i Mohanapriya Arumugam. "Computational investigation of marine bioactive compounds reveals frigocyclinone as a potent inhibitor of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) targets". Biomedical & Pharmacology Journal 12, nr 3 (21.08.2019): 1289–302. http://dx.doi.org/10.13005/bpj/1757.
Pełny tekst źródłaGordon, Erlinda Maria, Victoria S. Chua, Ted T. Kim, Neal Shiv Chawla, Don Arlen Brigham, Ishrat Bhuiyan, Mark Agulnik, Warren Allen Chow i Sant P. Chawla. "A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 11562. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.11562.
Pełny tekst źródłaFares Amer, Nasrin, i Tal Luzzatto Knaan. "Natural Products of Marine Origin for the Treatment of Colorectal and Pancreatic Cancers: Mechanisms and Potential". International Journal of Molecular Sciences 23, nr 14 (21.07.2022): 8048. http://dx.doi.org/10.3390/ijms23148048.
Pełny tekst źródłaSaada, Esma, Chahineze Rahal, Isabelle Ray Coquard, Antoine Italiano, Christine Chevreau, Nicolas Isambert, Binh Bui i in. "Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: The experience of the French Sarcoma Group (FSG)." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 10062. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10062.
Pełny tekst źródłaGrosso, F., G. D. Demetri, J. Y. Blay, I. Judson, A. Le Cesne, C. Spreafico, J. Jimeno, S. Pilotti, M. D’Incalci i P. G. Casali. "Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 9511. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.9511.
Pełny tekst źródłaDileo, P., F. Grosso, M. Casanova, J. Jimeno, S. Marsoni, R. Sanfilippo, M. Podda, S. Ferrari, R. Bertulli i P. G. Casali. "Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 10040. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10040.
Pełny tekst źródłaSouid, Soumaya, Dorra Aissaoui, Najet Srairi-Abid i Khadija Essafi-Benkhadir. "Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response". Current Drug Targets 21, nr 10 (28.07.2020): 996–1007. http://dx.doi.org/10.2174/1389450121666200128161733.
Pełny tekst źródłaSanfilippo, Roberta, Giacomo Giulio Baldi, Elena Fumagalli, Andrea Marrari, Rossella Bertulli, Elena Palassini, Silvia Stacchiotti, Michela Libertini i Paolo Giovanni Casali. "Safety of trabectedin (T) in elderly patients (pts) with advanced soft tissue sarcoma (STS)." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 10576. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.10576.
Pełny tekst źródłaDembitsky, Valery, Tatyana Gloriozova i Vladimir Poroikov. "Antitumor Profile of Carbon-Bridged Steroids (CBS) and Triterpenoids". Marine Drugs 19, nr 6 (3.06.2021): 324. http://dx.doi.org/10.3390/md19060324.
Pełny tekst źródłaMartinez-Trufero, Javier, Isabel Pajares, Alba Hernandez Garcia, Ana Cebollero, Lourdes Calera i Antonio Anton. "Efficacy of trabectedin for advanced soft tissue sarcoma (ASTS): A retrospective single center analysis." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): e21509-e21509. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e21509.
Pełny tekst źródłaLe Cesne, Axel, Isabelle Ray-Coquard, Florence Duffaud, Christine Chevreau, Nicolas Penel, Binh Bui, Sophie Piperno-Neumann i in. "A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 10563. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.10563.
Pełny tekst źródłaKampmann, Eric, Dominique Harnicek, Ana Sofia Cardoso Martins, Berina Eppink, Eike Gallmeier, Lars Lindner, Roland Kanaar i Rolf D. Issels. "Heat-shock (H-S) and trabectedin efficacy in human soft-tissue sarcoma (STS) cells in vitro." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): e13540-e13540. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13540.
Pełny tekst źródłaD'Incalci, Maurizio, Carlos Galmarini, Ines de la Riba Alvarez, Nadia Badri i Patrick Schöffski. "Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS)." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 10047. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10047.
Pełny tekst źródłaWang, Jun, Shihui Chen, Shiqiang Xu, Xing Yu, Dongqing Ma, Xiamin Hu i Xiaolu Cao. "In Vivo Induction of Apoptosis by Fucoxanthin, a Marine Carotenoid, Associated with Down-Regulating STAT3/EGFR Signaling in Sarcoma 180 (S180) Xenografts-Bearing Mice". Marine Drugs 10, nr 12 (20.09.2012): 2055–68. http://dx.doi.org/10.3390/md10092055.
Pełny tekst źródłaCioffi, A., A. LeCesne, J. Blay, S. Delaloge, A. Yovine, R. Maki, A. Nieto, J. J. Jiao i G. D. Demetri. "Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): e13510-e13510. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e13510.
Pełny tekst źródłaChawla, Sant P., Victoria S. Chua-Alcala, Katherine Kim, Nupur Assudani, Ahmad Al-Shihabi, Ania Moradkhani, Doris Quon i in. "The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma." Journal of Clinical Oncology 37, nr 8_suppl (10.03.2019): 22. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.22.
Pełny tekst źródłaAljahdali, Mohammed Othman, Mohammad Habibur Rahman Molla i Foysal Ahammad. "Compounds Identified from Marine Mangrove Plant (Avicennia alba) as Potential Antiviral Drug Candidates against WDSV, an In-Silico Approach". Marine Drugs 19, nr 5 (28.04.2021): 253. http://dx.doi.org/10.3390/md19050253.
Pełny tekst źródłaPawłowska, Natalia, Anna Czajkowska, Anna Bielawska i Krzysztof Bielawski. "Ecteinascidins – new antineoplastic drugs from the depths of the seas". Postępy Higieny i Medycyny Doświadczalnej 72 (13.12.2018): 1062–72. http://dx.doi.org/10.5604/01.3001.0012.7873.
Pełny tekst źródłaGordon, Erlinda M., Nadezhda Omelchenko, Samantha Jeffrey, Vaishali Kumar, Neal S. Chawla, Mahesh Seetharam, Victoria Chua i in. "Abstract CT287: LINNOVATE: A Phase 1/2 study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab for advanced soft tissue sarcomas (NCT05876715)". Cancer Research 84, nr 7_Supplement (5.04.2024): CT287. http://dx.doi.org/10.1158/1538-7445.am2024-ct287.
Pełny tekst źródłaBlay, J., M. von Mehren, B. L. Samuels, M. P. Fanucchi, I. L. Ray-Coquard, B. Buckley, L. Gilles, C. Lebedinsky, Y. A. Elsayed i A. Le Cesne. "Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): Safety and efficacy analysis". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 10078. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10078.
Pełny tekst źródłaXiao, Jin-Fen, Marina Broz, Roberta Piras, Kristin Ishaya, Emily Ko i Jlenia Guarnerio. "Abstract 1364: Profiling tumor microenvironment for therapeutic intervention to soft-tissue sarcomas". Cancer Research 83, nr 7_Supplement (4.04.2023): 1364. http://dx.doi.org/10.1158/1538-7445.am2023-1364.
Pełny tekst źródłaBehra, Biswadeep, S. Vairamuthu, Natesan Pazhanivel, Periyasamy Jalantha i Ganne Venkata Sudhakar Rao. "Histological and Immunohistochemical Features of Pulmonary Metastatic Oral Melanoma in a Labrador dog". Indian Journal of Veterinary Sciences & Biotechnology 18, nr 5 (7.11.2022): 119–22. http://dx.doi.org/10.48165/ijvsbt.18.5.24.
Pełny tekst źródłaGradl, Stefan, Sooncheol Lee, Martin Lange, Xiaoyun Wu, Silvia Goldoni, Timothy Lewis, Charlotte Kopitz i in. "Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy". Cancer Research 82, nr 12_Supplement (15.06.2022): ND04. http://dx.doi.org/10.1158/1538-7445.am2022-nd04.
Pełny tekst źródłaLeone, Francesco, Caterina Peraldo-Neia, Giuliana Cavalloni, Marco Soster, Loretta Gammaitoni, Serena Marchiò i Massimo Aglietta. "Preclinical evidence of ET-743 as a potential chemotherapy option for the treatment of biliary carcinoma." Journal of Clinical Oncology 31, nr 4_suppl (1.02.2013): 193. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.193.
Pełny tekst źródłaDel Campo, J., A. Roszak, T. Ciuleanu, M. Bidzinski, T. Hogberg, M. Wojtukienicz, K. Boman, A. Poveda, A. Westermann i M. Izquierdo. "Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 5031. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5031.
Pełny tekst źródłaPeyraud, Florent, Jean-Philippe Guegan, Christophe Rey, Marina Pulido, Emmanuelle Bompas, Sophie Piperno-Neumann, Christine Chevreau i in. "Abstract 2578: High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas". Cancer Research 82, nr 12_Supplement (15.06.2022): 2578. http://dx.doi.org/10.1158/1538-7445.am2022-2578.
Pełny tekst źródłaSalazar, R., B. Pardo, M. Majem, M. García, A. Montes, C. Cuadra, E. Ciruelos, H. Cortés-Funes, C. Lebedinsky i L. Paz-Ares. "Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 2080. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2080.
Pełny tekst źródłaSinko, J., J. Rajchard, Z. Balounova i L. Fikotova. " Biologically active substances from water invertebrates: a review". Veterinární Medicína 57, No. 4 (18.05.2012): 177–84. http://dx.doi.org/10.17221/5914-vetmed.
Pełny tekst źródłaBroz, Marina T., Marco DeSimone, Emily Ko, Roberta Piras i Jlenia Guarnerio. "Abstract A29: Uncovering transcriptional signatures of drug resistant tumor cells: Mechanisms of therapeutic resistance and opportunities for combination therapies". Cancer Immunology Research 10, nr 12_Supplement (1.12.2022): A29. http://dx.doi.org/10.1158/2326-6074.tumimm22-a29.
Pełny tekst źródłaBanella, Cristina, Laura Zocca, Alessia Boaretto, Gianluca Mattei, Marina Mola, Lara Ballerini, Lorito Nicla, Annalisa Tondo i Maura Calvani. "Abstract A108: Metabolic oriented treatment: efficacy of sr59230a 𝜷3-adrenergic receptor antagonist, and sr plus buformin® in Ewing sarcoma". Molecular Cancer Therapeutics 22, nr 12_Supplement (1.12.2023): A108. http://dx.doi.org/10.1158/1535-7163.targ-23-a108.
Pełny tekst źródłaBanella, Cristina, Francesco Carrozzo, Laura Zocca, Amada Pasha, Gianluca Mattei, Marina Mola, Lara Ballerini i in. "Abstract 1787: The β3-adrenergic receptor as novel target of metabolic phenotype in Ewing sarcoma". Cancer Research 84, nr 6_Supplement (22.03.2024): 1787. http://dx.doi.org/10.1158/1538-7445.am2024-1787.
Pełny tekst źródłaZENETOS, A., S. KATSANEVAKIS, D. POURSANIDIS, F. CROCETTA, D. DAMALAS, G. APOSTOLOPOULOS, C. GRAVILI, E. VARDALA-THEODOROU i M. MALAQUIAS. "Marine alien species in Greek Seas: Additions and amendments by 2010". Mediterranean Marine Science 12, nr 1 (11.03.2011): 95. http://dx.doi.org/10.12681/mms.55.
Pełny tekst źródłaBroz, Marina, Emily Ko, Jinfen Xiao, Marco DeSimone, Roberta Piras, Kristin Ishaya, Xen Ping Hoi i Jlenia Guarnerio. "Abstract 1255: Glucose dependent CD73+ CAFs enforce a tumor metabolic barrier that promotes T cell exclusion". Cancer Research 83, nr 7_Supplement (4.04.2023): 1255. http://dx.doi.org/10.1158/1538-7445.am2023-1255.
Pełny tekst źródłaLee, Meng-Chou, Chin-Yi Huang, Chin-Ling Lai, Han-Yang Yeh, Jing Huang, Wei Qing Chloe Lung, Po-Tsang Lee i Fan-Hua Nan. "Colaconema formosanum, Sarcodia suae, and Nostoc commune as Fermentation Substrates for Bioactive Substance Production". Fermentation 8, nr 7 (21.07.2022): 343. http://dx.doi.org/10.3390/fermentation8070343.
Pełny tekst źródłaGolozubova, Julia Sergeevna, Lyubov Stepanovna Buzoleva, Elena Aleksandrovna Bogatyrenko, Alexandra Vyacheslavovna Kim i Alena Igorevna Eskova. "Diversity of cultivated heterotrophic bacteria selected from surface waters of the Vostok Bay of the Japanese Sea". Samara Journal of Science 6, nr 4 (1.12.2017): 32–35. http://dx.doi.org/10.17816/snv201764106.
Pełny tekst źródłaAtmaca, Harika, Emir Bozkurt, Burcu Cakar, Zeki Gokhan Surmeli, Selim Uzunoglu, Ruchan Uslu i Burcak Karaca. "Trabectedin to induce mitochondrial membrane potential dissipation and reactive oxygen species generation in breast cancer cells." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): e13580-e13580. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13580.
Pełny tekst źródłaTaamma, A., J. L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J. M. Jimeno i E. Cvitkovic. "Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors". Journal of Clinical Oncology 19, nr 5 (1.03.2001): 1256–65. http://dx.doi.org/10.1200/jco.2001.19.5.1256.
Pełny tekst źródłaGanapathi, Shireen S., Emma Wrenn, Nicolas Garcia, Neerja Katiyar, Aya Miyaki, Yuqi Kang, Marina Chan, Taran S. Gujral i Elizabeth R. Lawlor. "Abstract 150: Transcriptional rewiring of BET inhibitor treated Ewing sarcoma cells augments their dependency on focal adhesion kinase". Cancer Research 84, nr 6_Supplement (22.03.2024): 150. http://dx.doi.org/10.1158/1538-7445.am2024-150.
Pełny tekst źródła